Mizuho lowered the firm’s price target on Medtronic to $90 from $100 and keeps a Buy rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Medtronic price target lowered to $78 from $90 at Truist
- Medtronic price target lowered to $80 from $88 at JPMorgan
- Medtronic put volume heavy and directionally bearish
- Needham biotechnology analysts to hold an analyst/industry conference call
- Wells sees preliminary injunction in Insulet case against EOFlow